
Over the past 12 months, we launched an aggressive plan to accelerate therapeutic development for FSH muscular dystrophy. Your support has brought us here, to this moment in history. And now, the future is in the same powerful hands ... yours.

**MILESTONES**

- **MARCH 12**
  - Industry collaborative workshop with FDA

- **JUNE 19-20**
  - 26th Annual International Research Congress, Marseille, France

- **SEPTEMBER**
  - Fulcrum Therapeutics launches ReDUX4 Phase 2 clinical trial

- **DECEMBER 3**
  - FSHD #Giving Tuesday Telethon

**FINANCIALS** (modified cash basis)

- **REVENUE RAISED**
  - $4.6 million

- **EXPENSES**
  - Community Development: $474,000
  - Administrative: $328,000

- **RESEARCH INVESTMENT**
  - $1.93 million

- **PATIENT EDUCATION & ENGAGEMENT**
  - $636,000

**GROWTH IN ENGAGEMENT**

- **NEW MEMBERS**
  - 2018: 2,300
  - 2019: 4,341

- **SUPPORTERS**
  - 2018: 3,281
  - 2019: 4,524

- **MEMBERS SERVED**
  - 2018: 4,667
  - 2019: 7,974

- **NUMBER OF WALKERS**
  - 2018: 542
  - 2019: 1,370

- **WEBINAR AUDIENCE**
  - 2018: 1,472
  - 2019: 3,460

- **CHAPTERS**
  - 2018: 17
  - 2019: 27

- **WALK & ROLL FUNDRAISERS**
  - 2018: 5
  - 2019: 11

**ACCELERATING RESEARCH**

- **RESEARCH INVESTMENT:** $1.93 million

- **INTERNATIONAL RESEARCH CONGRESS ATTENDEES:** 180

- **CLINICAL TRIAL RESEARCH NETWORK SITES:** 11

- **THERAPIES IN DEVELOPMENT:** 22

- **BIOTECH & PHARMA PARTNERS:** 9

[fshdsociety.org](http://fshdsociety.org)